UBS Group’s Zymeworks ZYME Stock Holding History

UBS Group’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-9,700	Closed	-$458K	–	9555
2020 Q4	$458K	Buy	+9,700	New	+$450K	﹤0.01%	4670

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

UBS Group's ZYME Position: Q1 2026 in Review

UBS Group reduced its Zymeworks (ZYME) stake by 38% in Q1 2026, selling an estimated $2.53M and leaving 171,779 shares worth $4.3M. The position accounts for ﹤0.01% of the portfolio, ranked #4227.

UBS Group first reported a position in ZYME in Q4 2017 and has held it in 32 quarters since. The position peaked at $7.34M in Q4 2025. 211 funds tracked by Wall St. Rank hold ZYME as of Q1 2026.

UBS Group held 171,779 shares of Zymeworks worth $4.3M as of Q1 2026.
UBS Group sold 107,075 Zymeworks shares in Q1 2026, an estimated $2.53M.
Zymeworks made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4227 holding.
UBS Group first reported a position in Zymeworks in Q4 2017 and has held it in 32 quarters since.
UBS Group's Zymeworks position peaked at $7.34M in Q4 2025.
211 funds tracked by Wall St. Rank held Zymeworks as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.